Experiences of immunotherapy cancer treatment: A Qualitative Study
Research type
Research Study
Full title
'Harnessing the little white cells': Tracing practices of immunity in cancer
IRAS ID
280228
Contact name
Julia Swallow
Contact email
Sponsor organisation
University of Edinburgh
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Over the last five years, immunotherapy treatments have emerged in clinical practice and are also
currently being tested as part of experimental clinical trials to treat patients with some forms of
cancer. These treatments utilise the patient's own body to treat cancer and the scientific and clinical hope attached to these novel therapies is that they have the potential to extend survival time for patients. There are however, clinical concerns regarding long-term treatment side-effects and toxicities, predicting response and prognosis, and management of patients’ hopes and expectations.This research is a qualitative ethnographic study exploring how novel immunotherapy treatments are implemented in order to understand how these treatments are shifting how cancer is approached, managed and experienced. I will interview patients, healthcare practitioners and scientists, and observe clinical consultations and laboratory work. I want to see how cancer takes shape and with what consequences as these novel therapies are implemented, considering how immunotherapy treatments impact how cancer is managed in clinical practice as part of patient care as well as exploring what these developments mean for patients who are living with cancer. This data and analysis will be useful for an improved understanding of the impact of biomedical innovation on patients' experiences as well as the practice of healthcare. It is anticipated that this work will help change health policy for the better, and improve care for patients living with advanced cancer.
REC name
North of Scotland Research Ethics Committee 2
REC reference
20/NS/0062
Date of REC Opinion
19 Jun 2020
REC opinion
Further Information Favourable Opinion